SCP & CO Healthcare Acquisition Company, a blank check company formed by SCP & CO targeting the healthcare industry, has raised $200 million for its IPO after pricing its 20 million shares at $10 per share. The stock began trading January 22, 2021 on the NASDAQ under the ticker symbol “SHACU.” Barclays Capital Inc. and Piper Sandler & Co are the underwriters.
Tampa, FL. January 21, 2021. SCP & CO Healthcare Acquisition Company (the “Company”), announced today the pricing of its upsized initial public offering of 20,000,000 units at a price of $10.00 per unit. The units are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) on January 22, 2021 under the symbol “SHACU”. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “SHAC” and “SHACW”, respectively.
SCP & CO Healthcare Acquisition Company is a blank check company organized under the laws of Delaware. While the Company may pursue an initial business combination in any industry, sector or geographical location, it intends to initially focus its search on identifying a prospective target business in the healthcare technology or healthcare-related industries in the United States and other developed countries. The Company is led by Scott N. Feuer, its Chief Executive Officer; Bryan L. Crino, its President; and Joseph M. Passero, its Chief Financial Officer. The Company’s Board of Directors consists of Messrs. Feuer and Crino, and also Alan Gold, Tim Main, Randy Parker, and R. David Kretschmer.
Barclays Capital Inc. and Piper Sandler & Co. are acting as joint bookrunning managers of the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial offering price to cover over-allotments, if any.
The offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from: Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at Barclaysprospectus@broadridge.com or by telephone at (888) 603-5847, and/or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, by telephone at (800) 747-3924, or by email at email@example.com.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on January 21, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.